-
These 8 drugs face FDA regulatory review decision in January 2020
Time of Update: 2019-12-27
Last Friday, AstraZeneca and HER2, the first three joint venture product, got the approval of the US FDA in advance unexpectedly, which is much earlier than the target date of PDUFA in April 2020 Acco
-
Continued research and development of natural small molecule anti-cancer! Inventory of anti-tumor natural product molecules
Time of Update: 2019-12-21
Since the 1940s, human beings began to use small molecule drugs to treat tumors Alkylating agents, fluorouracil, methotrexate, cyclophosphamide and a series of other drugs have been put on the market
-
Yan is just one word! How do MAH and pharmaceutical companies implement the new "Drug Administration Law
Time of Update: 2019-12-02
The new drug administration law of the people's Republic of China (hereinafter referred to as the new drug administration law) has been revised and adopted by the 12th meeting of the Standing Committe
-
Immunotherapy for lung cancer! AstraZeneca immunofinzi + tremelimumab immune combination first-line treatment of phase III clinical failure
Time of Update: 2019-08-23
August 23, 2019 / bioun / -- AstraZeneca, a British pharmaceutical giant, recently announced the final overall survival (OS) results of Neptune, a phase III clinical study of PD-L1 tumor immunotherapy
-
The R & D investment is 16 million yuan, lasting for 7 years, and the new drug shagliptin tablet of aosaikang pharmaceutical industry is approved to go on the market
Time of Update: 2019-01-22
On January 21, Beijing Oriental New Star Petrochemical Engineering Co., Ltd announced that its holding subsidiary Jiangsu aosaikang Pharmaceutical Co., Ltd (hereinafter referred to as "aosaikang pharm
-
19 retail pharmacies in Zhanjiang, Guangdong have passed GSP certification
Time of Update: 2018-12-06
Announcement of GSP certification of pharmaceutical trading enterprises in Zhanjiang City, Guangdong Province c-gd-18-zj No.05 According to the provisions of the drug administration law of the people'
-
The expected difference of sales of lenalidomine in the future is 10 billion US dollars, causing great controversy in the industry
Time of Update: 2018-11-05
Evaluate Pharma, a pharmaceutical market research organization, recently published an analysis of the most controversial products expected to be sold in the biopharmaceutical industry in the future Am
-
AstraZeneca's $1 billion variety first imitated and temporarily approved by hualuohaizheng pharmaceutical
Time of Update: 2018-10-17
On October 16, Haizheng pharmaceutical announced that its holding subsidiary, Haizheng Hangzhou company, had obtained temporary approval for the Anda (American generic drug application) of tegrilol ta
-
Preparation and case analysis of DMF for chemical imitation API
Time of Update: 2018-04-08
The author introduces Jiang Qiao, Ph.D in physicochemistry, Nankai University, and postdoctoral in pharmaceutical chemistry, Zhejiang University Currently, he is the director of synthetic R & D in the
-
Priority evaluation and favorable evaluation: Top 3 of the most beneficial domestic pharmaceutical companies, with a closer look at the performance of key varieties after listing
Time of Update: 2017-12-26
Since the first batch of priority review varieties at the beginning of 2016, 25 batches of priority review catalogue have been issued, involving nearly 391 acceptance numbers The latest batch of publi
-
Let's listen to me too
Time of Update: 2017-12-01
Source: US China Pharmaceutical source [news event] on December 1, 2017: today, Bruce booth, a famous biotechnology investor, published a blog to review the achievements of the pharmaceutical industry
-
FDA takes basic steps to improve the acquisition of brand drug samples by generic companies
Time of Update: 2017-11-10
Source: Scott Gottlieb, director of FDA of synlin 2017-11-10, has been focusing on FDA's efforts to curb the abuse risk assessment and mitigation strategy (REMS) system of brand companies to block the
-
CBIO's hemophilia B drug was awarded the title of orphan drug by FDA
Time of Update: 2017-09-29
Source: Biovalley 2017-09-29 today, CBIO (catalyst Biosciences) announced that FDA awarded the company's CB 2679d / isu304 orphan drug for the treatment of hemophilia B CB 2679d / isu304 is a subcutan
-
Do you have the right choice of captopril
Time of Update: 2017-06-16
Recently, CFDA released the catalogue of six batches of reference preparations in three times, which caused a howl in the industry This article will take captopril tablet as an example to discuss the
-
FDA grants oncosec immunopulse IL-12 fast channel designation
Time of Update: 2017-02-28
Source: Sina Pharma 2017-2-28 photo source: Oriental IC, Inc on February 27, San Diego time, oncosec company, which focuses on DNA-based intratumoral cancer immunotherapy, said that the U.S FDA grante
